10-K: SpyGlass Pharma 2025 10-K: Glaucoma System Advances to Phase 3

SpyGlass Pharma, Inc. reports significant progress in its BIM-IOL System for glaucoma, initiating two Phase 3 clinical trials and completing a successful IPO in early 2026, despite ongoing financial losses.

Summary

• SpyGlass Pharma is a late-stage biopharmaceutical company focused on long-acting, sustained drug delivery for chronic eye conditions.
• The lead product candidate, the Bimatoprost Drug Pad-IOL System (BIM-IOL System), is designed for implantation during routine cataract surgery to reduce elevated intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT), aiming for three years of bimatoprost delivery.
• First-in-human (FIH) trial results showed a mean IOP reduction of 37% at 36 months, with 95% of evaluable patients off topical IOP-lowering drops and no product-related adverse events (AEs).
• Phase 1/2 trial results demonstrated mean IOP reductions of 37% (78 mcg dose) and 36% (39 mcg dose) at three months, sustained at twelve months, with 97% of treated patients off topical drops.
• Two registrational Phase 3 trials were initiated in July 2025, each expected to enroll approximately 400 patients across 45 sites, with enrollment projected to complete in 2027.
• A 505(b)(2) New Drug Application (NDA) submission to the FDA is planned for 2028, contingent on successful Phase 3 results.
• The company is also developing a non-IOL-based, ring-shaped sustained-release implant (BIM-DRS) for standalone procedures, retreatment, and pseudophakic patients, with FIH trials planned for 2026.
• The estimated total addressable market in the United States for the BIM-IOL System is approximately $13 billion.
• Net losses were $39.9 million in 2025 and $29.2 million in 2024, resulting in an accumulated deficit of $104.7 million as of December 31, 2025.
• An Initial Public Offering (IPO) was completed in February 2026, raising approximately $156.1 million in net proceeds.
• Cash and cash equivalents and short-term investments totaled $107.4 million as of December 31, 2025.
• Management believes existing capital, including IPO proceeds, will fund operating expenses and capital expenditure requirements through 2028.
• A material weakness in internal control over financial reporting was identified, related to insufficient personnel, lack of effective risk assessment, and inadequate segregation of duties.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive filing. While the company reported significant financial losses and faces substantial risks inherent in biopharmaceutical development, the positive clinical trial data for the BIM-IOL System and the successful IPO provide a strong foundation for future development and commercialization efforts. The clear path to Phase 3 and planned NDA submission are key milestones, but the long timeline to profitability and reliance on a single lead product temper the overall sentiment.

Positives

• Lead product candidate, BIM-IOL System, demonstrated sustained IOP reduction of 37% at 36 months in FIH trial, with 95% of patients off topical drops and no product-related AEs.
• Phase 1/2 trial showed consistent IOP reductions (34-42%) at 12 months, with 98% of evaluable patients free from topical IOP-lowering medications in the 78-mcg group and 96% in the 39-mcg group.
• BIM-IOL System was well-tolerated in both FIH and Phase 1/2 trials, with few reported ocular hyperemia cases and no serious ocular AEs observed at 12 months in Phase 1/2.
• Initiation of two registrational Phase 3 clinical trials in July 2025, with first patients randomized in January 2026, marks significant development progress.
• The BIM-IOL System is designed to integrate seamlessly into routine cataract surgery, potentially tripling the number of cataract surgeons who treat OAG/OHT.
• Anticipated streamlined regulatory approval via FDA's 505(b)(2) pathway due to bimatoprost being a previously approved active ingredient.
• Favorable payor environment expected, with Medicare Part B coverage and potential for a new J-code for the physician-administered drug, offering incremental revenue for providers and facilities.
• Estimated total addressable market in the United States for the BIM-IOL System is approximately $13 billion.
• Proprietary SpyGlass Platform is scalable and expandable, designed for various approved medicines and eye conditions (AMD, postoperative care, chronic uveitis).
• Strong intellectual property portfolio with 15 issued U.S. patents and 11 issued foreign patents, expiring between 2039 and 2043.
• Experienced leadership team with a proven track record in ophthalmology, drug-device combination products, and IOLs.
• Successful completion of an IPO in February 2026, raising approximately $156.1 million net proceeds, providing funding through 2028.

Negatives

• Incurred significant net losses of $39.9 million in 2025, an increase from $29.2 million in 2024, indicating worsening financial performance.
• Accumulated deficit grew to $104.7 million as of December 31, 2025.
• No products approved for commercial sale and no revenue generated from product sales to date.
• Substantial dependence on the success of the lead product candidate, the BIM-IOL System; failure to complete development or obtain approval would significantly harm the business.
• High capital requirements for ongoing development and future commercialization, with a need for substantial additional capital beyond 2028.
• Intense competition from large pharmaceutical, biotechnology, medical technology, and ophthalmology companies with greater financial resources.
• The active pharmaceutical ingredient (bimatoprost) is in the public domain, limiting patent protection for the drug itself and exposing the company to competition from third parties using the same API.
• Identified a material weakness in internal control over financial reporting, which could affect financial reporting accuracy and stock price if not remediated.
• Subject to a legal proceeding filed by Glaukos Corporation alleging trade secret misappropriation and other claims, with trial set for October 27, 2026.
• The company's operations are concentrated in California, making it vulnerable to natural disasters like wildfires and earthquakes.

Risks

• Limited operating history and no products approved for commercial sale, making future success and viability difficult to evaluate.
• Anticipation of continued significant losses and potential inability to achieve or maintain profitability.
• Substantial dependence on the success of the BIM-IOL System; failure in development, approval, or commercialization would harm the business.
• Even if approved, product candidates may fail to achieve market acceptance by surgeons, patients, and the medical community.
• Significant competition from companies with greater resources and potentially more effective, safer, or less expensive products.
• Need for substantial additional capital beyond 2028, which may cause dilution or force delays/reductions in R&D programs.
• Dependence on intellectual property rights granted under the license agreement with the Regents of the University of Colorado; loss of this license could prevent product development.
• Inability to obtain and maintain sufficient intellectual property protection for technology and product candidates, allowing competitors to commercialize similar products.
• Patent application process is subject to numerous risks and uncertainties, with no assurance of successful patent issuance or defense.
• Potential involvement in third-party claims of intellectual property infringement, which could delay or prevent commercialization.
• Regulatory approval processes are lengthy, time-consuming, and unpredictable; inability to obtain approval would prevent revenue generation.
• Clinical trials may not demonstrate safety and efficacy to the satisfaction of regulatory authorities or produce positive results.
• Product candidates may become subject to unfavorable third-party coverage and reimbursement policies, as well as pricing regulations.
• Success is highly dependent on the ability to attract and retain highly skilled executive officers and employees.
• Reliance on third parties (CROs, clinical investigators) to conduct preclinical studies and clinical trials; failure by these parties could harm the business.
• Reliance on third-party contract manufacturing organizations (CMOs) for product candidates; risks of insufficient quantities, unacceptable costs, or non-compliance with cGMP.
• Identified a material weakness in internal control over financial reporting, which could lead to inaccurate financial reporting or fraud.
• Implantation of the BIM-IOL System involves risks and potential complications (infection, inflammation, dislocation, AEs), which may limit adoption.
• Mechanical failure of BIM-IOL System components (e.g., haptic breakage) during trials or commercial use could delay approval or limit adoption.
• The active pharmaceutical ingredient (bimatoprost) is in the public domain, exposing the company to competition and supply risks.
• Risk of expending limited resources on less profitable or less successful product candidates or indications.
• Changes in U.S. trade policy, including tariffs, could increase material costs or delay development.
• Uncertainty in U.S. and foreign patent laws, particularly for drug delivery technology and medical devices, could adversely impact existing or future patents.
• Patent terms may be inadequate to protect competitive position for a sufficient amount of time.
• Risk of not identifying relevant third-party patents or incorrectly interpreting their relevance, scope, or expiration.
• Noncompliance with procedural requirements for patent maintenance could reduce or eliminate patent protection.
• Potential involvement in lawsuits to protect or enforce patents, which are expensive and time-consuming.
• Inability to protect intellectual property rights in all foreign jurisdictions.
• Risk of trade secret misappropriation or wrongful use/disclosure of confidential information by employees or third parties.
• Claims that employees, consultants, or contractors have wrongfully used or disclosed confidential information of former employers or other third parties.
• Claims that former employers, consultants, or third parties have an ownership interest in the company's patents.
• Intellectual property rights may not address all potential threats to competitive advantage.
• Failure to comply with obligations under license agreements (e.g., with University of Colorado) could lead to termination and loss of IP rights.
• Unsuccessful collaboration or partnership arrangements.
• Inability to license or acquire additional necessary intellectual property rights or technology from third parties.
• Intellectual property discovered through government-funded programs may be subject to federal regulations (e.g., march-in rights, U.S.-based manufacturing preference).
• Litigation, government investigations, and enforcement actions could adversely affect the business.
• Risks associated with marketing product candidates internationally (differing regulations, economic instability, compliance with foreign laws).
• Volatility in common stock trading price.
• Significant influence of principal stockholders and management over matters subject to stockholder approval.
• Potential for significant decline in stock price due to future sales of restricted shares.
• Future sales and issuances of common stock or rights to purchase common stock could result in additional dilution.
• Board of directors authorized to issue preferred stock without stockholder approval, potentially diluting common stock value.
• Reduced reporting requirements as an emerging growth company may make common stock less attractive to certain investors.
• No anticipated cash dividends for the foreseeable future.
• Delaware law and company bylaws might delay, discourage, or prevent a change in control or management.
• Bylaws designate Delaware courts as exclusive forum for certain disputes, potentially limiting stockholders' choice of forum.
• Claims for indemnification by directors and officers may reduce available funds.
• Increased costs and demands on management due to public company compliance.
• Inadequate insurance policies or unrecoverable risks.
• Subject to U.S. and foreign export/import controls, sanctions, anti-corruption, and anti-money laundering laws.
• Changes in income tax rates or other indirect taxes may affect financial results.
• Ability to use net operating loss carryforwards and other tax attributes may be limited by ownership changes (Section 382/383).
• Unstable market and economic conditions, including financial services industry disruptions, may adversely affect business.

Future Outlook

The company expects to complete enrollment in its two registrational Phase 3 trials for the BIM-IOL System by 2027 and plans to submit a 505(b)(2) NDA to the FDA in 2028, pending successful Phase 3 results. It anticipates reporting 12-month data from Phase 3 in 2028 and 24-month data in 2029. The BIM-DRS is planned to advance into first-in-human trials in 2026, subject to ongoing animal study outcomes. Management believes existing cash and IPO proceeds will fund operations through 2028, but substantial additional capital will be required thereafter for development and commercialization.

Management Comments

• Our mission is to significantly improve the lives of patients with chronic eye conditions by developing durable drug delivery solutions that can empower patients and surgeons with confidence in long-term disease control and vision preservation.
• We believe our BIM-IOL System has the potential to triple the number of cataract surgeons who treat OAG or OHT routinely at the time of cataract surgery by providing a solution that seamlessly integrates into the existing procedural workflow.
• We believe our approach positions us to pursue a streamlined regulatory approval process under the FDAs 505(b)(2) pathway because the active ingredient in our BIM-IOL System, bimatoprost, has been previously approved by the FDA.
• We anticipate that use of the BIM-IOL System, if approved, will be reimbursed through established reimbursement pathways, including Medicare Part B coverage, and we intend to leverage existing Category I Current Procedural Terminology (CPT) codes for the cataract surgery and apply for a new J-code for the physician-administered drug.
• By combining a known drug (bimatoprost), a known procedure (cataract surgery), and a known device type (IOL), the BIM-IOL System aims to deliver a solution that addresses both cataracts and elevated IOP in a single, streamlined intervention.
• We believe this presents an opportunity for providers and facilities, including ASCs, where approximately 90% of cataract surgeries in the United States are performed, to recognize incremental revenue from cataract surgeries.
• We believe that the net proceeds from our IPO, together with our existing cash and cash equivalents and short-term investments at December 31, 2025, will be sufficient to fund our operating expenses and capital expenditure requirements through 2028.

Industry Context

StockSavvy.ai notes that SpyGlass Pharma operates in the highly competitive and rapidly advancing ophthalmology and biopharmaceutical industries, characterized by a strong emphasis on intellectual property. The company's focus on long-acting, sustained drug delivery for chronic eye conditions like glaucoma addresses a significant unmet need for improved patient adherence and ease of administration, particularly given the high non-compliance rates with daily eye drops (up to 80%). The strategy to integrate glaucoma treatment with routine cataract surgery positions SpyGlass to potentially disrupt the existing market by expanding the pool of treating surgeons beyond MIGS specialists, who currently represent only one-third of active cataract surgeons. This approach could significantly increase market penetration compared to traditional MIGS devices or novel intracameral implants that require specialized training and workflow changes. The estimated $13 billion U.S. addressable market for the BIM-IOL System highlights the substantial opportunity if market acceptance and favorable reimbursement are achieved.

Comparison to Industry Standards

• Patient Adherence: The BIM-IOL System aims to overcome the notoriously poor patient adherence (up to 80% non-compliance, nearly 50% discontinuation within one year) associated with daily topical IOP-lowering eye drops, which is the current standard of care for glaucoma.
• Surgical Integration: Unlike Minimally Invasive Glaucoma Surgery (MIGS) procedures, which require specialized skills and training (only one-third of 10,000 active U.S. cataract surgeons perform MIGS routinely), the BIM-IOL System is designed to seamlessly integrate into existing routine cataract surgery workflows, potentially tripling the number of surgeons who can treat OAG/OHT.
• Drug Delivery Duration: The BIM-IOL System is designed to deliver bimatoprost consistently for three years, offering a significantly longer-acting solution compared to daily topical drops or shorter-duration implants like Durysta (which typically lasts for several months).
• Dose Profile: The BIM-IOL System uses an ultralow dose of bimatoprost, less than a 5mL bottle of topical drops, potentially reducing the risk of common PGA side effects like ocular hyperemia (reported in ~45% of topical bimatoprost users).
• Reimbursement: The company anticipates leveraging existing Category I CPT codes for cataract surgery and applying for a new J-code for the physician-administered drug, similar to other physician-administered drugs like iDose TR (J7355) and Durysta (J7351), which are typically reimbursed at ASP plus 6%. This contrasts with other implantable glaucoma devices that often require new, less established CPT codes.
• Clinical Efficacy (IOP Reduction): The 37% mean IOP reduction observed in the FIH trial and 34-42% in Phase 1/2 for the BIM-IOL System is comparable to or better than the ~30% IOP reduction typically achieved with topical bimatoprost (Lumigan product label).

Management Changes

Corporate Governance

Legal Proceedings

• On September 17, 2025, Glaukos Corporation filed a lawsuit in the U.S. District Court for the Central District of California against SpyGlass Pharma and employee Long Doan (Case No. 8:25-cv-02105).
• Glaukos alleges trade secret misappropriation under the federal Defend Trade Secrets Act and California's unfair competition statute against SpyGlass Pharma.
• Glaukos alleges breach of contract, fraud regarding employee exit documentation, and a violation of the Computer Fraud and Abuse Act against Mr. Doan.
• Requested remedies include judgment of misappropriation, seizure of computers for deletion of trade secrets, temporary/preliminary/permanent injunctions, damages, attorneys' fees, interest, and potential future royalty payments.
• On October 6, 2025, Glaukos filed a motion for a preliminary injunction, which was denied by the court on December 11, 2025, regarding employment restrictions. The court ordered forensic review of alleged trade secret information.
• On November 18, 2025, SpyGlass and Mr. Doan filed motions to dismiss the complaint.
• On January 26, 2026, the court indicated it was likely to grant SpyGlass's motion to dismiss Glaukos' unfair competition law claim with prejudice.
• Trial in the matter has been set for October 27, 2026.
• SpyGlass believes it has meritorious defenses and intends to defend the case vigorously, but acknowledges the outcome is uncertain and costs could be material.

Related Party Transactions

• **University of Colorado Medicine (CU Medicine) Services Agreement**: The company has a services agreement with CU Medicine for the services of Dr. Malik Y. Kahook (co-founder, president, chief medical officer, executive chair). Payments to CU Medicine were $0.3 million in 2025 and $0.3 million in 2024. The monthly rate was $24,150 until February 26, 2025, then increased to $24,995 for the remainder of 2025. As of March 1, 2026, Dr. Kahook's consulting fee increased to $34,000 per month, with an annual target bonus of $163,200.
• **Redeemable Convertible Preferred Stock Financings**: In March 2025, the company issued 4,933,589 shares of Series C-2 preferred stock for $50.0 million to investors including entities affiliated with RA Capital (Zach Scheiner, Ph.D.), New Enterprise Associates (Ali Behbahani, M.D.), Samsara BioCapital (Michael Dybbs, Ph.D.), and Vensana Capital I, L.P. (Kirk Nielsen). In May and June 2025, the company issued 5,799,465 shares of Series D preferred stock for $77.3 million to investors including entities affiliated with New Enterprise Associates (Ali Behbahani, M.D.), RA Capital (Zach Scheiner, Ph.D.), Vensana Capital I, L.P. (Kirk Nielsen), and Samsara BioCapital (Michael Dybbs, Ph.D.).
• **Participation in IPO (February 2026)**: Certain holders of more than 5% of capital stock and entities affiliated with directors purchased shares. This included entities affiliated with RA Capital ($59,040,000), New Enterprise Associates ($15,000,000), Samsara Opportunity Fund, L.P. ($10,000,000), Sands Capital Alternatives ($10,000,000), Coperatieve Gilde Healthcare VG VI U.A. ($5,000,000), Vensana Capital I, L.P. ($2,640,000), New World Medical, Inc. ($1,840,000), and Bilal Khan ($320,000).
• **Investors Rights Agreement**: The company is party to an amended and restated investors rights agreement with certain holders of its capital stock, including entities affiliated with New Enterprise Associates, RA Capital, Sands Capital Alternatives, Samsara BioCapital, Vensana Capital I, L.P., and Coperatieve Gilde Healthcare VG VI U.A., granting demand and piggyback registration rights. Most rights terminated upon IPO, except registration rights.
• **Voting Agreement**: The company was previously party to an amended and restated voting agreement with certain holders of its capital stock, including Patrick Mooney, Malik Y. Kahook, M.D., and affiliates of major investors. This agreement terminated upon IPO.
• **Indemnification Agreements**: The company has entered into or will enter into separate indemnification agreements with each of its directors and executive officers.

Stakeholder Impact

• **Shareholders**: Potential for long-term value creation if BIM-IOL System is successfully developed and commercialized in a large market. IPO provides liquidity and capital for growth. Positive clinical data supports future prospects. However, significant dilution from past and future capital raises is expected. High volatility in stock price is anticipated. Risk of substantial losses continuing for the foreseeable future. Concentration of ownership by principal stockholders and management could limit influence of other shareholders. Legal proceedings and intellectual property challenges pose risks to investment.
• **Employees**: Equity incentive plans (2019 Plan, 2026 Plan, ESPP) provide opportunities for ownership and long-term incentives. Growth of the company could lead to career advancement. However, there is a risk of termination for policy violations (e.g., insider trading). Potential for increased workload and pressure due to rapid growth and public company demands.
• **Customers (Surgeons/Patients)**: The BIM-IOL System offers a potential long-term, sustained drug delivery solution for glaucoma, reducing reliance on daily eye drops and improving patient adherence. Seamless integration into cataract surgery could simplify treatment for surgeons and patients. However, risks are associated with any surgical procedure and implantable device (e.g., AEs, mechanical failure). Uncertainty of regulatory approval and market acceptance exists.
• **Suppliers/Creditors**: Continued business relationships with CMOs and CROs for manufacturing and clinical trials. However, there is a risk of non-payment or renegotiation of terms if the company faces financial difficulties. Dependence on third-party manufacturers for critical components is noted.
• **Regulatory Bodies**: The company's commitment to compliance with FDA regulations and other healthcare laws is positive. However, there is potential for increased scrutiny, investigations, fines, or delays if regulatory requirements are not met or if issues arise with product safety/efficacy.

Next Steps

• Complete enrollment in two registrational Phase 3 clinical trials by 2027.
• Submit a 505(b)(2) New Drug Application (NDA) to the FDA in 2028, pending successful Phase 3 results.
• Report 12-month data from Phase 3 trials in 2028.
• Report 24-month data from Phase 3 trials in 2029.
• Advance the BIM-DRS into first-in-human (FIH) trials in 2026, subject to ongoing animal study outcomes.
• Continue market feasibility and technical viability assessments for other eye conditions (AMD, postoperative eye care, chronic uveitis).
• Strengthen global intellectual property portfolio through new filings.
• Opportunistically evaluate strategic partnerships to maximize platform value.
• Remediate the identified material weakness in internal control over financial reporting by hiring additional accounting personnel.
• Prepare for commercial launch of BIM-IOL System if approved, including developing internal commercialization capability.
• Apply for a Healthcare Common Procedure Coding System (HCPCS) Permanent J-code for the physician-administered drug component of the BIM-IOL System.
• Consider applying for a new add-on Category III CPT code for the loading, implantation, and position of the Drug Pad-IOL System.
• Conduct annual penetration testing and periodic red team exercises as part of cybersecurity maturity roadmap in 2026.
• Transition to new headquarters in Irvine, California, commencing July 1, 2026.

Key Dates

Recommendation

The company has demonstrated promising clinical results for its lead product, the BIM-IOL System, and has successfully completed an IPO, providing a significant capital infusion. This progress is a strong positive for future development. However, the company is still in the late-stage clinical phase with no approved products or revenue, incurring substantial and increasing losses. The identified material weakness in internal controls and ongoing litigation add layers of operational and financial risk. While the long-term market opportunity is significant, the path to profitability is distant and uncertain, warranting a "hold" recommendation for seasoned investors who should monitor Phase 3 trial results, regulatory progress, and financial management closely before considering further investment.

Keywords

Biopharmaceutical, Ophthalmology, Glaucoma, Ocular Hypertension, Cataract Surgery, Drug Delivery System, Bimatoprost, Intraocular Pressure (IOP), IOL (Intraocular Lens), Sustained Release, Clinical Trials, Phase 3, FDA Approval, 505(b)(2) Pathway, Medical Device, Drug-Device Combination, Biotech, Pharmaceutical, SEC Filing, 10-K, IPO, Risk Management, Intellectual Property, Corporate Governance